LLY
Eli Lilly and Company
- Operating cash flow, 2025
- $16.8B
- YoY, 2025
- +90.7%
- 5-year CAGR
- +20.9%
- 10-year CAGR
- +19.0%
Operating cash flow
Operating cash flow by fiscal year
| Period | Operating cash flow | YoY |
|---|---|---|
| 2025 | $16.8B | +90.7% |
| 2024 | $8.8B | +108.0% |
| 2023 | $4.2B | −44.1% |
| 2022 | $7.6B | +3.0% |
| 2021 | $7.4B | +13.3% |
| 2020 | $6.5B | +34.4% |
| 2019 | $4.8B | −12.5% |
| 2018 | $5.5B | −1.6% |
| 2017 | $5.6B | +15.8% |
| 2016 | $4.9B | +63.6% |
| 2015 | $3.0B | −33.5% |
| 2014 | $4.5B | −22.3% |
| 2013 | $5.7B | +8.1% |
| 2012 | $5.3B | −26.7% |
| 2011 | $7.2B | +5.5% |
| 2010 | $6.9B | +58.2% |
| 2009 | $4.3B | −40.6% |
| 2008 | $7.3B | +41.5% |
| 2007 | $5.2B | — |